1Andrew CG, Drachman DB, Pestrunk A, et al. Susceptibility of skeletal muscle to Coxsackie A2 virus infection: effects of botulium toxin and denervation. Science, 1984, 223: 714-716.
2Zoll J, Jongen P, Galama J, et al. Coxsackievims B1-induced murine myosistis: no evidence for viral persistence. J Gen Viral,1993, 74: 2071-2076.
3Travers RL, Hughes GR, Cambridge G, et al. Coxsackie B neutralisation titles in polymyositis/dermatomyositis. Lancet, 1977,1 : 1268.
5Douche-Aourik F, Berlier W, Feasson L, et al. Detection of entervirus in human skeletal muscle from patients with chronic inflammatory muscle disease or fibromyalgia and healthy subjects. J Med Virol, 2003, 71: 540-547.
6Buttinelli G, Donati V, Ruggefi FM, et al. Antigenic sites of coxsackie A9 virus inducing neutralizing monoclonal antibodies protective in mice. Virology, 2003, 312: 74-83.
7Gomez RM, Rinehart JE, Wollmann R, et al. Theiler' s murine encephalomyelitis virus-induced cardiac and skeletal muscle disease.J Virol, 1996,70 : 8926-8933.
8Rosenberg NL, Rotbart HA, Abzug MJ, et al. Evidence for a novel picomavirus in human dermatomyosltis. Ann Neurol, 1989, 26:204 -209.
9Ruff RL, Secrist D. Viral studies in benign acute childhood myositis. Arch Neurol, 1982, 39: 261-263.
10Yoshino M, Suzuki S, Adachi K, et al. High incidence of acute myositis with type A influenza virus infection in the elderly. Intern Med, 2000, 39: 431-432.
